Vagus Nerve Stimulation trials

tVNS in Long COVID-19

RecruitingNCT06585254Phase: NAStarted 2024-11-01

Summary

A prior open label study has shown that transcutaneous vagus nerve stimulation \[tVNS\] can improve the health of some patients with postacute sequelae of SARS-CoV-2 infection (PASC), severely affecte

Eligibility

Sex
ALL
Min Age
21 Years
Max Age
70 Years

Locations

Icahn School of Medicine at Mount SinaiNew York, New York, United States

View full study details on ClinicalTrials.gov

clinicaltrials.gov/study/NCT06585254